Kringle Pharma, Inc.
Notice Regarding Proposals to Be Submitted to the Ordinary General Meeting of Shareholders
A proposal to appoint seven directors will be submitted at the ordinary general meeting of shareholders. The candidates consist of six incumbent members (including reappointments) and two external candidates (Koichiro Yoshino and Masato Fukui), totaling seven. The proposal also specifies terms such as the independence of the external director candidates and directors' liability insurance.
Key Figures
- Number of director candidates: 7
- External director candidates among the nominees: 2 (Koichiro Yoshino, Masato Fukui)
- Shareholdings: The shares held by each candidate are as stated (e.g.: 108,400 shares, 15,000 shares, 17,000 shares, 15,000 shares, 7,500 shares, etc.)
AI要約
Overview of Director Candidates
A proposal to appoint seven directors will be submitted at this general meeting. The candidates include incumbents Kiichi Adachi, Koichi Murakami, Chiharu Oshiro, Yoshiyuki Kayano, Masahiro Tomoyasu, and external candidates Koichiro Yoshino and Masato Fukui. Mr. Yoshino has been registered as an independent officer, and Mr. Fukui is an external director candidate who serves as President and CEO of Xenoack Holdings / Xenogen Pharma, reflecting the relationship between the major shareholder Xenoack Group and the Company.
Conditions of Appointment and Insurance for Directors
If the proposed candidates assume office, the Company intends to continue contracts based on the limits of liability prescribed by Article 427, Paragraph 1 of the Companies Act and the Company's Articles of Incorporation. Additionally, the Company will enter into directors' and officers' liability insurance contracts to cover damages arising from the execution of duties. The tenure for the external candidates is eight years for Mr. Yoshino and six years for Mr. Fukui.
Kringle Pharma, Inc.
Company overview · Stock price · Financial data · All IR